The goal of this observational study is to evaluate the diagnostic accuracy of CBCT dose reduction on the mandibular canal visibility, and their effect on canal cortication compared to standard CBCT dose as a gold standard. The main question it aims to answer is: Will the lower CBCT doses affect the visualization of mandibular canal when compared to standard CBCT dose as a gold standard?
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Primary outcome Evaluation of the diagnostic accuracy of the lowest CBCT dose (Milliampere: 2.2 mA.) compared to the gold standard CBCT dose (Milliampere: 10 mA.) on the mandibular canal visibility.
Timeframe: March 2024